Sun Pharmaceutical Industries and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. announced the signing of addendums to the license and supply agreements for WINLEVI (clascoterone) cream 1% expanding the territory to include Japan, Australia, New Zealand, Brazil, Mexico and Russia. In 2021, Sun Pharma and Cassiopea had signed License and Supply Agreements for the United States and Canada markets. Sun Pharma launched WINLEVI in the US market in November 2021.
Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma') for WinleviTM (clascoterone cream 1%) for the US and Canada.
Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, 'Sun Pharma') for WinleviTM (clascoterone cream 1%) for the US and Canada.
Dublin, Ireland – 10 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced the resignation, due to his retirement, of Dr. Hans Christoph Tanner as a non-executive board member and the proposal for the appointment of Mr. David Maris as a new non-executive board member, both to take effect from the next AGM on the 28th of May.
RedHill Biopharma has entered agreements with Cosmo Pharmaceuticals to manufacture two key products: RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Dublin, Ireland – 5 February 2021: Cosmo Pharmaceuticals NV (SIX: COPN) today announced that it has licensed the EU rights (plus Switzerland, UK, EEA countries, Russia and Mexico) for Lumeblue™ to Alfasigma S.p.A. Lumeblue™ is Cosmo’s recently EMA approved drug for the detection of lesions during colonoscopy.
RedHill Biopharma, a specialty biopharmaceutical company, has formed a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib to address prospective demand subsequent to potential global emergency use authorizations.